المؤلفون: Hillier, Peter R, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Ben M., Walewska, Renata, Furtado, Michelle, Preston, Gavin, Nelson, Jeffrey R, Pemberton, Nicholas, Sidra, Gamal, Morley, Nicholas H., Cwynarski, Kate, Schuh, Anna H., Forconi, Francesco, Elmusharaf, Nagah, Paneesha, Shankara, Fox, Christopher, Howard, Dena R., Hockaday, Anna, Brown, Julia, Cairns, David A., Jackson, Sharon (Shae) Margaret, Greatorex, Natasha, Webster, Nichola, Shingles, Jane, Dalal, Surita, Patten, Piers E.M., Allsup, David, Rawson, Andrew David, Munir, Talha

وصف الملف: text

العلاقة: https://eprints.soton.ac.uk/477713/1/1_s2.0_S1470204523001444_main.pdfTest; Hillier, Peter R, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Ben M., Walewska, Renata, Furtado, Michelle, Preston, Gavin, Nelson, Jeffrey R, Pemberton, Nicholas, Sidra, Gamal, Morley, Nicholas H., Cwynarski, Kate, Schuh, Anna H., Forconi, Francesco, Elmusharaf, Nagah, Paneesha, Shankara, Fox, Christopher, Howard, Dena R., Hockaday, Anna, Brown, Julia, Cairns, David A., Jackson, Sharon (Shae) Margaret, Greatorex, Natasha, Webster, Nichola, Shingles, Jane, Dalal, Surita, Patten, Piers E.M., Allsup, David, Rawson, Andrew David and Munir, Talha (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5), 535-552. (doi:10.1016/S1470-2045(23)00144-4 ).

الإتاحة: https://doi.org/10.1016/S1470-2045Test(23)00144-4
https://eprints.soton.ac.uk/477713Test/
https://eprints.soton.ac.uk/477713/1/1_s2.0_S1470204523001444_main.pdfTest

المؤلفون: Hillmen, Peter, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Ben, Walewska, Renata, Furtado, Michelle, Preston, Gavin, Neilson, Jeffrey R, Pemberton, Nicholas, Sidra, Gamal, Morley, Nicholas, Cwynarski, Kate, Schuh, Anna, Forconi, Francesco, Elmusharaf, Nagah, Paneesha, Shankara, Fox, Christopher P., Howard, Dena R., Hockaday, Anna, Brown, Julia M., Cairns, David A., Jackson, Sharon, Greatorex, Natasha, Webster, Nichola, Shingles, Jane, Dalal, Surita, Patten, Piers E. M., Allsup, David, Rawstron, Andrew, Munir, Talha

مصطلحات موضوعية: Cyclophosphamide, Female, Male, State Medicine, Middle Aged, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Rituximab, Humans

العلاقة: https://nottingham-repository.worktribe.com/output/21097706Test; The Lancet Oncology; Volume 24; Issue 5; Pagination 535-552; https://nottingham-repository.worktribe.com/file/21097706/1/Ibrutinib%20and%20rituximab%20versus%20fludarabine,%20cyclophosphamide,%20and%20rituximab%20for%20patients%20with%20previously%20untreated%20chronic%20lymphocytic%20leukaemia%20%28FLAIRTest

الإتاحة: https://doi.org/10.1016/S1470-2045%2823%2900144-4Test
https://doi.org/10.1016/S1470-2045Test(23)00144-4
https://nottingham-repository.worktribe.com/file/21097706/1/Ibrutinib%20and%20rituximab%20versus%20fludarabine,%20cyclophosphamide,%20and%20rituximab%20for%20patients%20with%20previously%20untreated%20chronic%20lymphocytic%20leukaemia%20%28FLAIRTest
https://nottingham-repository.worktribe.com/output/21097706Test

المؤلفون: Hillmen, Peter, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Ben, Walewska, Renata, Furtado, Michelle, Preston, Gavin, Neilson, Jeffrey R., Pemberton, Nicholas, Sidra, Gamal, Morley, Nicholas, Cwynarski, Kate, Schuh, Anna, Forconi, Francesco, Elmusharaf, Nagah, Paneesha, Shankara, Fox, Christopher P., Howard, Dena R., Hockaday, Anna, Brown, Julia M., Cairns, David A., Jackson, Sharon, Greatorex, Natasha, Webster, Nichola, Shingles, Jane, Dalal, Surita, Patten, Piers E.M., Allsup, David, Rawstron, Andrew, Munir, Talha

المصدر: Hillmen , P , Pitchford , A , Bloor , A , Broom , A , Young , M , Kennedy , B , Walewska , R , Furtado , M , Preston , G , Neilson , J R , Pemberton , N , Sidra , G , Morley , N , Cwynarski , K , Schuh , A , Forconi , F , Elmusharaf , N , Paneesha , S , Fox , C P , Howard , D R , Hockaday , A , Brown , J M , Cairns , D A , Jackson , ....

الإتاحة: https://doi.org/10.1016/S1470-2045Test(23)00144-4
https://kclpure.kcl.ac.uk/portal/en/publications/4f8d495f-3091-430f-867e-4474e87d148fTest
http://www.scopus.com/inward/record.url?scp=85154071902&partnerID=8YFLogxKTest

المؤلفون: Howard, Dena R., Hockaday, Anna, Brown, Julia M., Gregory, Walter M., Todd, Susan, Munir, Tahla, Oughton, Jamie B, Dimbleby, Claire, Hillmen, Peter

وصف الملف: text

العلاقة: https://centaur.reading.ac.uk/95444/1Test/Howard%20et%20al_2021_Trials.pdf; Howard, D. R., Hockaday, A., Brown, J. M., Gregory, W. M., Todd, S. orcid:0000-0002-9981-923X , Munir, T., Oughton, J. B., Dimbleby, C. and Hillmen, P. (2021) A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials, 22 (1). 38. ISSN 1745-6215 doi: https://doi.org/10.1186/s13063-020-04971-2Test

الإتاحة: https://doi.org/10.1186/s13063-020-04971-2Test
https://centaur.reading.ac.uk/95444Test/
https://centaur.reading.ac.uk/95444/1Test/Howard%20et%20al_2021_Trials.pdf

المؤلفون: Wojdacz, Tomasz K., Amarasinghe, Harindra E., Kadalayil, Latha, Beattie, Alice, Forster, Jade, Blakemore, Stuart J., Parker, Helen, Bryant, Dean, Larrayoz, Marta, Clifford, Ruth, Robbe, Pauline, Davis, Zadie A., Else, Monica, Howard, Dena R., Stamatopoulos, Basile, Steele, Andrew J., Rosenquist, Richard, Collins, Andrew, Pettitt, Andrew R., Hillmen, Peter, Plass, Christoph, Schuh, Anna, Catovsky, Daniel, Oscier, David G., Rose-Zerilli, Matthew J.J., Oakes, Christopher C., Strefford, Jonathan C.

المصدر: Wojdacz , T K , Amarasinghe , H E , Kadalayil , L , Beattie , A , Forster , J , Blakemore , S J , Parker , H , Bryant , D , Larrayoz , M , Clifford , R , Robbe , P , Davis , Z A , Else , M , Howard , D R , Stamatopoulos , B , Steele , A J , Rosenquist , R , Collins , A , Pettitt , A R , Hillmen , P , Plass , C , Schuh , A , Catovsky , D , ....

مصطلحات موضوعية: CLL PATIENTS, CYCLOPHOSPHAMIDE, FCR, FLUDARABINE, GENE, MUTATIONS, PROGRESSION, REMISSIONS, RITUXIMAB, SURVIVAL, Prognosis, Epigenesis, Genetic, Humans, Middle Aged, Male, Gene Expression Profiling, Computational Biology/methods, DNA Methylation, Aged, 80 and over, Adult, Female, Epigenomics/methods, Proportional Hazards Models, Gene Expression Regulation, Leukemic, Leukemia, Lymphocytic, Chronic

العلاقة: https://pure.au.dk/portal/en/publications/4de291fb-4e4b-411a-8af7-c044cf86e358Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2019000237Test
https://pure.au.dk/portal/en/publications/4de291fb-4e4b-411a-8af7-c044cf86e358Test
http://www.scopus.com/inward/record.url?scp=85071580517&partnerID=8YFLogxKTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712529/pdf/advancesADV2019000237.pdfTest

المؤلفون: Alharthi, Afaf, Beck, Daniel, Howard, Dena R., Hillmen, Peter, Oates, Melanie, Pettitt, Andrew, Wagner, Simon D.

مصطلحات موضوعية: Chronic lymphocytic leukaemia, Extracellular vesicle, miRNA

العلاقة: https://www.ncbi.nlm.nih.gov/pubmed/29739419Test; BMC Research Notes, 2018, 11:280; https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9Test; http://hdl.handle.net/2381/42178Test

الإتاحة: https://doi.org/10.1186/s13104-018-3391-9Test
http://hdl.handle.net/2381/42178Test

المؤلفون: Collett, Laura, Howard, Dena R., Munir, Talha, McParland, Lucy, Oughton, Jamie B., Rawstron, Andy C., Hockaday, Anna, Dimbleby, Claire, Phillips, David, McMahon, Kathryn, Hulme, Claire, Allsup, David, Bloor, Adrian, Hillmen, Peter

المصدر: Collett , L , Howard , D R , Munir , T , McParland , L , Oughton , J B , Rawstron , A C , Hockaday , A , Dimbleby , C , Phillips , D , McMahon , K , Hulme , C , Allsup , D , Bloor , A & Hillmen , P 2017 , ' Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial) : Study protocol for a phase III randomised controlled trial ' , Trials , vol. 18 , no. 1 , 387 . https://doi.org/10.1186/s13063-017-2138-6Test

مصطلحات موضوعية: Clinical trial, CLL, FCR, Front-line, Ibrutinib, Minimal residual disease (MRD), Phase III, Randomised, Rituximab, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre

الإتاحة: https://doi.org/10.1186/s13063-017-2138-6Test
https://research.manchester.ac.uk/en/publications/1e8fd3a5-68c2-4ceb-bf06-48d3aaaa7d53Test
http://www.scopus.com/inward/record.url?scp=85028010374&partnerID=8YFLogxKTest

المؤلفون: Oughton, JB, Collett, Laura, Howard, Dena R, Hockaday, Anna, Munir, Talha, McMahon, Kathryn, McParland, Lucy, Dimbleby, Claire, Phillips, David, Rawstron, Andy C, Hillmen, Peter

المصدر: Oughton , JB , Collett , L , Howard , D R , Hockaday , A , Munir , T , McMahon , K , McParland , L , Dimbleby , C , Phillips , D , Rawstron , A C & Hillmen , P 2017 , ' GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial : study protocol for a phase II/III randomised controlled trial. ' , Trials , vol. 18 , 353 . https://doi.org/10.1186/s13063-017-2107-0Test

مصطلحات موضوعية: Chronic lymphocytic leukaemia (CLL), Obinutuzumab, GA-101, Consolidation, Phase II/III trial, Minimal residual disease (MRD), Randomised controlled trial (RCT)

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1186/s13063-017-2107-0Test
https://hdl.handle.net/1983/df7fd9b6-5282-43ab-a9e1-a7ace74e9143Test
https://research-information.bris.ac.uk/en/publications/df7fd9b6-5282-43ab-a9e1-a7ace74e9143Test
https://research-information.bris.ac.uk/ws/files/210561098/s13063_017_2107_0.pdfTest

المؤلفون: Howard, Dena R., Munir, Talha, Hockaday, Anna, Rawstron, Andy C., Collett, Laura, Oughton, Jamie B., Allsup, David, Bloor, Adrian, Phillips, David, Hillmen, Peter

المصدر: Howard , D R , Munir , T , Hockaday , A , Rawstron , A C , Collett , L , Oughton , J B , Allsup , D , Bloor , A , Phillips , D & Hillmen , P 2016 , ' Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial : Study protocol for a phase II randomised controlled trial ' , Trials , vol. 17 , no. 1 , 456 . https://doi.org/10.1186/s13063-016-1581-0Test

مصطلحات موضوعية: Bendamustine, CLL, Chronic lymphocytic leukaemia, Dose selection, FC, MRD, Minimal residual disease, Ofatumumab, Phase II trial, Randomised clinical trial, Relapsed population

الإتاحة: https://doi.org/10.1186/s13063-016-1581-0Test
https://research.manchester.ac.uk/en/publications/732d1548-8458-4c0f-ab33-f9e3e809b267Test
http://www.scopus.com/inward/record.url?scp=84988493287&partnerID=8YFLogxKTest

المؤلفون: Gregory, Walter M., Twelves, Christopher J., Bell, Richard, Smye, Stephen W., Howard, Dena R., Coleman, Robert E., Cameron, David A.

المساهمون: Novartis Pharmaceuticals Corporation

المصدر: Breast Cancer Research and Treatment ; volume 155, issue 2, page 303-311 ; ISSN 0167-6806 1573-7217

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1007/s10549-016-3684-4Test